What were Regeneron's second-quarter revenue and adjusted earnings per share, and how did they compare to analyst estimates?

Regeneron's second-quarter revenue rose 17% to $4.29 billion, surpassing analyst estimates of $3.82 billion; its non-GAAP adjusted profit was $14.29 per share, beating the analyst estimate of $10.26 per share.

How did Dupixent and the high-dose version of Eylea contribute to Regeneron's second-quarter performance?

Global net sales of Dupixent—recorded by partner Sanofi—increased 38% to about $6 billion, exceeding LSEG estimates of $5.34 billion; U.S. sales of the high-dose (8-mg) version of Eylea rose 52% to $596 million, driven by higher demand and sales volumes, partially offset by lower prices, while sales of the lower-dose version were hurt by competitive pressures and patient transitions to the 8-mg version.

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Jul 30, 2026

Regeneron exceeded Q2 revenue and profit estimates, driven by a 38% increase in Dupixent sales and strong high-dose Eylea performance. Shares rose nearly 5% after reporting $4.29 billion in quarterly revenue.

reuters

2026-07-30

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Regeneron beats quarterly estimates on eczema drug strength, shares rise

FAQ